Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis - a case series

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e832-e833. doi: 10.1111/jdv.18311. Epub 2022 Jun 21.

Authors

G Feraru^{1

2}, M J Nevet^{1

3}, L Samuelov^{4

5}, E Hodak^{5

6}, E Avitan-Hersh^{1

3}, M Ziv^{1

2}, R P Dodiuk-Gad^{1

2

7}

Affiliations

¹ Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
² Division of Dermatology, Emek Medical Center, Afula, Israel.
³ Division of Dermatology, Rambam Health Care Campus, Haifa, Israel.
⁴ Division of Dermatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
⁵ Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
⁶ Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
⁷ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

PMID: 35680538
DOI: 10.1111/jdv.18311

No abstract available

Publication types

Letter

MeSH terms

Adult
Dermatitis, Atopic* / drug therapy
Heterocyclic Compounds, 3-Ring / adverse effects
Humans
Severity of Illness Index
Treatment Outcome

Substances

Heterocyclic Compounds, 3-Ring
upadacitinib